Market Place
Sourcing Support
Esperion campaign sheds light on ‘Lipid Lurkers’ in artery walls
16 Jul 2024 //
FIERCE PHARMA
Enforcement Report - Week of April 24, 2024
24 Apr 2024 //
FDA
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
22 Mar 2024 //
BUSINESSWIRE
FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET®
22 Mar 2024 //
BUSINESSWIRE
Esperion & Daiichi Sankyo Announce $125 Million Amendment to Their Collaboration
03 Jan 2024 //
BUSINESSWIRE
Esperion, Daiichi resolve dispute with $125M settlement
03 Jan 2024 //
FIERCE PHARMA
Enforcement Report - Week of September 13, 2023
13 Sep 2023 //
FDA
Cholesterol-focused Esperion loses appetite for Serometrix pact
01 Aug 2023 //
FIERCE BIOTECH
Esperion hits Nexletol partner Daiichi with lawsuit
28 Mar 2023 //
FIERCE PHARMA
Esperion in dispute with Daiichi over drug milestone payment
17 Mar 2023 //
BIOPHARMADIVE
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Session
19 Dec 2022 //
PRESS RELEASE
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 Dec 2022 //
PRESS RELEASE
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL
08 Dec 2022 //
PRESS RELEASE
Esperion Appoints Ben Halladay CFO
16 Nov 2022 //
GLOBENEWSWIRE
Esperion Announces the Appointment of J. Martin Carroll toits Board of Directors
05 Jun 2022 //
YAHOO
Esperion Therapeutics: Q1 Earnings Insights
03 May 2022 //
BENZINGA
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data
02 May 2022 //
ESPERION
Esperion to Participate in Upcoming Bank of America Securities 2022 Conference
29 Apr 2022 //
PRESS RELEASE
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
29 Apr 2022 //
PRESS RELEASE
Esperion Appoints Stephen Rocamboli to its Board of Directors
28 Apr 2022 //
PRESS RELEASE
Esperion Supports Collaborative Study with NC to Study the Effects of NEXLIZET
25 Apr 2022 //
PRESS RELEASE
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
19 Apr 2022 //
PRESS RELEASE
Esperion Publishes PIII Data on Bempedoic Acid in Journal of Clinical Lipidology
13 Apr 2022 //
PRESS RELEASE
Esperion Announces Two NEXLETOL Data Presentations at the ACC
03 Apr 2022 //
PRESS RELEASE
Esperion Announces Proposed Public Offering
02 Dec 2021 //
GLOBENEWSWIRE
AHA 2021 – Merck’s oral cholesterol lowerer could heap more misery on Esperion
15 Nov 2021 //
EVALUATE
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
15 Nov 2021 //
BIOSPACE
Esperion Reports Q3 2021 Financial Results and Provides Company Update
02 Nov 2021 //
PRNEWSWIRE
Esperion to Present Key Science at the American Heart Association Scientific
01 Nov 2021 //
GLOBENEWSWIRE
Checkmate CEO exits one-asset biotech, board member fills post
28 Oct 2021 //
FIERCEBIOTECH
Esperion to cute 170 staffers as heart disease pill sputters
19 Oct 2021 //
YAHOOFINANCE
ESPERION Announces Plan for Transformative Long-Term Growth
18 Oct 2021 //
GLOBENEWSWIRE
Esperion lays off nearly half its workforce as heart drug sales disappoint
18 Oct 2021 //
BIOPHARMADIVE
On the heels of a stinging Q1 setback, Esperion`s longtime champion
17 May 2021 //
ENDPTS
ESPERION Reports First Quarter 2021 Financial Results
04 May 2021 //
GLOBENEWSWIRE
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
27 Apr 2021 //
GLOBENEWSWIRE
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
26 Apr 2021 //
GLOBENEWSWIRE
NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination
17 Mar 2021 //
GLOBENEWSWIRE
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results
13 Jan 2021 //
GLOBENEWSWIRE
What if a pill could lower cholesterol like pricey injectables?
13 Jan 2021 //
STATNEWS
Esperion`s new Nexletol analyses build its case with doctors
14 Nov 2020 //
FIERCE PHARMA
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company
02 Nov 2020 //
GLOBENEWSWIRE
Esperion launches DTC campaign for Nexletol with all-stock video
01 Oct 2020 //
FIERCE PHARMA
Esperion`s first drug debut story during pandemic
21 Sep 2020 //
FIERCE PHARMA
Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
31 Aug 2020 //
FIERCE PHARMA
Esperion Reports Second Quarter 2020 Financial Results and Provides Update
10 Aug 2020 //
GLOBENEWSWIRE
Here`s how 4 drugmakers are using digital tools
18 Jun 2020 //
FIERCE PHARMA
Here`s how 4 drugmakers are using digital tools
18 Jun 2020 //
FIERCE PHARMA
Esperion Announces Pooled Analysis from Ph3 LDL-C Lowering Devp of NEXLETOL
14 Jun 2020 //
GLOBENEWSWIRE
ICER to Assess Treatments for High Cholesterol
12 Jun 2020 //
ICER
Esperion & Otsuka to develop treatment for hypercholesterolemia
22 Apr 2020 //
BIOSPECTRUMASIA
Esperion strikes Japan deal for `goldilocks` cholestrol drug, bags $60M cash
20 Apr 2020 //
COM
Esperion Therapeutics (ESPR) Announces EC Approval of NUSTENDI Tablet
06 Apr 2020 //
STREETINSIDER
Esperion`s Nexletol busts cholesterol levels regardless , ezitimibe therapy
30 Mar 2020 //
ESPERION
Esperion Announces Pooled Analyses from Ph3 LDL-C Lowering NEXLETOL™
23 Mar 2020 //
GLOBENEWSWIRE
Sage confirms suspension of 2 depression trials after PhIII flop
28 Feb 2020 //
ENDPTS
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
28 Feb 2020 //
FIERCE PHARMA
Esperion gets FDA thumbs up for cholesterol drug Nexletol
26 Feb 2020 //
PMLIVE
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet
21 Feb 2020 //
GLOBENEWSWIRE
Esperion scores FDA nod for cholesterol-buster Nexletol
21 Feb 2020 //
FIERCEPHARMA
